Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEOCON-F: Neo-Adjuvant Chemotherapy and Conservative Surgery in Cervical Cancer
NCT03852979Phase 2Terminated
- Sponsor
- Netherlands Cancer Institute
- Start
- Nov 2018
- Primary completion
- Jan 2020
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel and carboplatin in Cervical Cancer (CC), sponsored by Netherlands Cancer Institute. Primary endpoints: Efficacy of neo-adjuvant chemotherapy at 6 weeks and Safety of neo-adjuvant chemotherapy at 2 years. Started Nov 2018; status: terminated.
02
Drugs
paclitaxelcarboplatin
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT03852979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03852979.